Contera Pharma Aps

Mads Kreilgaard

John Bondo Hansen

Mikael S Thomsen

Peter G Nielsen

Jens Damsgaard Mikkelsen

Peter Gudmund Nielsen

Jens D Mikkelsen

The present invention provides a pharmaceutical formulation for oral administration comprising an agonist of two or more of the 5-HT1B, 5-HT1D and 5-HT1F receptors, such as a triptan, e.g. zolmitriptan, in a matrix constituent with extended release characteristics, and further comprising a 5-HT1A-R agonist, such as buspirone, in a constituent with immediate-release characteristics. The special formulation is particularly well-suited for use in the treatment of movement disorders by combining the two active ingredients in a manner that achieves synergy from both the combination per se and the special release parameters of the pharmaceutical formulation, allowing for ease of administration and reducing the risk of adverse effects of each of the two active ingredients.

Growing community of inventors

Farum, Denmark

Mads Kreilgaard